US OptionsDetailed Quotes

PCRX241220P12500

Watchlist

0.10
0.000.00%

15min DelayClose Nov 25 16:00 ET

0.00High0.00Low

Pacira BioSciences Stock Discussion

Value investorr

Aug 23 11:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

Value investorr

Aug 19 10:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss

Mr Long Term

Aug 13 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

Value investorr

Aug 12 09:29

A golden opportunity

$Pacira BioSciences (PCRX.US)$ Let’s layout their current situation and see if the market has priced it appropriately:
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue...

Shroomie

Aug 9 15:03

pew pew.. in and out in 30 seconds

$Pacira BioSciences (PCRX.US)$

Share Your Profit/Loss

Moomoo AI

Mar 14 08:53

Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.

Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding

Moomoo AI

Feb 4 09:04

Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.

Should Weakness in Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Moomoo AI

Jan 9 08:22

Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.

Pacira BioSciences Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution

Moomoo AI

Nov 24, 2023 12:47

The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.

The Three-year Earnings Decline Is Not Helping Pacira BioSciences' (NASDAQ:PCRX Share Price, as Stock Falls Another 4.3% in Past Week

vincentts

Oct 12, 2021 03:07

$Pacira BioSciences (PCRX.US)$ $Flexion Therapeutics (FLXN.US)$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.

No comment yet